← Back to Patent Explorer
US5362308A Expired / Lapsed US ⏱️ 0.0 years remaining

Disposable dosage unit for iontophoresis-facilitated transdermal delivery, related devices and processes

Assignee: Rutgers, The State University of New Jersey
•
Filing: 1993-10-05
•
Granted: 1994-11-08
•
Expires: 2013-10-05
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Provided are disposable dosage units for use in iontophoresis-facilitated transdermal delivery which have hydrophilic polymer first and second layers, the first layer having ionic resin particles dispersed therein and the second layer having an ionized pharmaceutical contained. The second layer having on its surface a thin fabric layer bearing an adhesive layer. The polymer first and second layers are separated by a permselective membrane. Also provided are related devices and processes using the novel disposable dosage units.

Inventors

  • 👤 Yie W. Chien
  • 👤 Li-Lan H. Chen

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-08 06:50
CPC Classifications
A; A61; A61N; A61N1/00; A61N1/18; A61N1/20; A61N1/30; A61K; A61K9/00; A61K9/0002; A61K9/0009; A61N1/02; A61N1/04; A61N1/0404; A61N1/0408; A61N1/0428; A61N1/0444; A61N1/0448

Claims Analysis

Total Claims: 12
Claim 1
Independent Claim 314 words
A pharmaceutical dosage unit adapted to be removably assembled with a reservoir electrode of a transdermal periodic iontotherapeutic system, said dosage unit to be used in electrical contact with intact skin to be iontotherapeutically treated to administer transdermally a systemically effective dose amount of an effective and transdermally absorbable amount of an ionized pharmaceutical; said dosage unit comprising solution of said ionized pharmaceutical dispersed therein having an iontotherapeutically effective and physiologically acceptable pH at least about one pH unit lower or higher than the pKa or isoelectric point of said pharmaceutical; said unit dose adapted to permit said pharmaceutical to be released upon application to the reservoir electrode of an effective pulsed DC current; said dosage unit having the following elements: a. a dimensionally stable hydrophilic gel polymer first layer which comprises a hydrophilic polymer which has dispersed therein an ionic exchange resin which is effective in removing the ions generated by the electrode during the operation of the iontotherapeutic system; b. a permselective membrane is intimately adhered to the top surface of the hydrophilic polymer layer which has a pores size sufficiently small to prevent any substantial passage of the pharmaceutical through the membrane; c. a hydrophilic gel polymer second layer intimately adhered to the top surface of the permselective membrane and having dispersed therein an effective dose amount of an ionized pharmaceutical solution, said solution having a pH at least one pH unit below or above the pKa or isoelectric point of the pharmaceutical; d. a thin fabric disc intimately adhered to the hydrophilic gel polymer second layer; and e. an adhesive polymer third layer being in intimate contact with the thin fabric disc and providing intimate contact with the skin of a subject being treated; said dosage unit adapted to be received by the pharmaceutical reservoir electrode and to make electrical contact with the electrical terminus of said pharmaceutical reservoir electrode.
Claim 2
Dependent Claim 314 words
A pharmaceutical dosage unit adapted to be removably assembled with a reservoir electrode of a transdermal periodic iontotherapeutic system, said dosage unit to be used in electrical contact with intact skin to be iontotherapeutically treated to administer transdermally a systemically effective dose amount of an effective and transdermally absorbable amount of an ionized pharmaceutical; said dosage unit comprising solution of said ionized pharmaceutical dispersed therein having an iontotherapeutically effective and physiologically acceptable pH at least about one pH unit lower or higher than the pKa or isoelectric point of said pharmaceutical; said unit dose adapted to permit said pharmaceutical to be released upon application to the reservoir electrode of an effective pulsed DC current; said dosage unit having the following elements: a. a dimensionally stable hydrophilic gel polymer first layer which comprises a hydrophilic polymer which has dispersed therein an ionic exchange resin which is effective in removing the ions generated by the electrode during the operation of the iontotherapeutic system; b. a permselective membrane is intimately adhered to the top surface of the hydrophilic polymer layer which has a pores size sufficiently small to prevent any substantial passage of the pharmaceutical through the membrane; c. a hydrophilic gel polymer second layer intimately adhered to the top surface of the permselective membrane and having dispersed therein an effective dose amount of an ionized pharmaceutical solution, said solution having a pH at least one pH unit below or above the pKa or isoelectric point of the pharmaceutical; d. a thin fabric disc intimately adhered to the hydrophilic gel polymer second layer; and e. an adhesive polymer third layer being in intimate contact with the thin fabric disc and providing intimate contact with the skin of a subject being treated; said dosage unit adapted to be received by the pharmaceutical reservoir electrode and to make electrical contact with the electrical terminus of said pharmaceutical reservoir electrode.
Claim 3
Dependent Claim 18 words
A dosage unit of claim 1 wherein the polymer used to make the polymer second layer is polyacrylamide.
Claim 4
Dependent Claim 18 words
A dosage unit of claim 1 wherein the polymer used to make the polymer first layer is polyacrylamide.
Claim 5
Dependent Claim 11 words
A dosage unit of claim 1 wherein the pharmaceutical is insulin.
Claim 6
Dependent Claim 11 words
A dosage unit of claim 1 wherein the pharmaceutical is LHRH.
Claim 7
Dependent Claim 30 words
A dosage unit of claim 1 wherein the pH is at least about 2 pH units below or above the pH of the pKa or isoelectric point of the pharmaceutical.
Claim 8
Dependent Claim 17 words
A dosage unit of claim 1 wherein the pharmaceutical is insulin and the pH is about 3.6.
Claim 9
Dependent Claim 21 words
A dosage unit of claim 1 wherein one or both of the polymer first or second layers is made using HEMA.
Claim 10
Dependent Claim 20 words
A dosage unit of claim 1 wherein the polymer first layer has a thin fabric disc laminated to its surface.
Claim 11
Dependent Claim 32 words
A dosage unit of claim 1 wherein the dosage unit has a housing element holding the dosage unit which is adapted for assembly with the reservoir electrode of the iontotherapeutic system used.
Claim 12
Dependent Claim 20 words
A protective pouch which contains a dosage unit of claim 1 and protects the dosage unit for storage and shipment.

References Cited (Backward Citations)

US4383529A Cited
US4702732A Cited
US4722726A Cited
US4915685A Cited
US5135480A Cited
US5042975A Cited
US4786277A Cited
US4731049A Cited
US4927408A Cited
US5080646A Cited
US5084008A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1997-11-07 1998-05-09 1998-11-08 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2001-11-07 2002-05-09 2002-11-08 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2005-11-07 2006-05-09 2006-11-08 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag